For durvalumab, an anti-PD-L1 antibody drug, a phase II study in patients with dMMR colorectal cancers and phase I/II studies in patients with dMMR solid tumors were conducted and demonstrated an efficacy with the ORR for colorectal cancers of 22% and an overall ORR of 23% [68]. Here, CD274 is linked to colorectal cancer.